Cargando…
The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC
Autor principal: | Cortellini, Alessio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474225/ https://www.ncbi.nlm.nih.gov/pubmed/34589959 http://dx.doi.org/10.1016/j.jtocrr.2020.100080 |
Ejemplares similares
-
Letter Regarding “Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma”
por: Wang, Yinhan, et al.
Publicado: (2022) -
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
por: Das, Satya, et al.
Publicado: (2019) -
Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019) -
Mucocutaneous adverse events to immune checkpoint inhibitors
por: Muhaj, Fiorinda, et al.
Publicado: (2023) -
Unexpected Adverse Events of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2023)